Apyx Medical Corp (APYX) SEC Filings

Apyx Medical Corporation reported Q2 2026 sales of $13,884 (in thousands), up 22.1% year over year, and six‑month sales of $26,374 (in thousands), up 26.8%. Growth was driven by the Surgical Aesthetics segment, which rose 28.1% in Q2 and 31.7% year to date, helped by AYON Body Contouring, higher handpiece volumes and stronger international generator sales.

Gross margin improved to 63.9% in Q2 and 63.7% for the first half. The company still posted losses: Q2 net loss attributable to stockholders was $3,243 (in thousands), with a six‑month net loss of $5,351 (in thousands), or basic and diluted loss per share of $0.07 and $0.12, respectively. Cash and cash equivalents were $27,617 (in thousands) at June 30, 2026; net cash used in operating activities was $4,062 (in thousands) for the first half.

Apyx carries a $37,500 (in thousands) term loan under its Perceptive Credit Agreement at a 12.0% interest rate and remains in covenant compliance, including Surgical Aesthetics revenue and operating expense targets. The company disclosed ongoing product liability matters with recorded defense cost accruals and a new patent infringement lawsuit filed July 20, 2026, while also highlighting expanded FDA 510(k) clearance for AYON power liposuction and a limited commercial launch started in late June.

Apyx Medical Corporation reported that on August 6, 2026 it issued a press release presenting its results of operations for the second quarter ended June 30, 2026. The press release is provided as Exhibit 99.1 and is incorporated by reference.

The company states that this earnings information is furnished under Item 2.02 of the Exchange Act, rather than filed for purposes of Section 18 or automatically incorporated into other Securities Act or Exchange Act reports unless specifically referenced. The report also identifies a Cover Page Interactive Data File, prepared using Inline XBRL, as Exhibit 104.

On July 24, 2026, Apyx Medical Corporation reported that its Board of Directors reconstituted the membership and chairs of its standing committees.

Following his appointment as Executive Chairman effective June 11, 2026, Stavros Vizirgianakis will not serve on any Board committee. The Board determined that Mr. Waldman, Ms. Baylor-Henry, and Ms. Levine are independent under applicable Nasdaq Global Select Market and SEC rules and that Mr. Waldman qualifies as an audit committee financial expert under SEC regulations.

Royce & Associates reports amended beneficial ownership of Apyx Medical Corporation common stock. The firm beneficially owns 3,274,064 shares, representing 7.81% of the class as of June 30, 2026. It has sole power to vote and dispose of all reported shares and no shared voting or dispositive power.

The shares are held in investment management accounts of clients of Royce & Associates, LP, an indirect majority-owned subsidiary of Franklin Resources, Inc. Royce & Associates states the holdings are maintained in the ordinary course of business, disclaims pecuniary interest and beneficial ownership beyond Rule 13d-3, and indicates the position is not held to change or influence control of Apyx Medical Corporation.

Apyx Medical Corp director Lawrence Waldman reported a routine stock option exercise with tax withholding. On June 30, 2026, a Spousal Lifetime Access Trust associated with him exercised 12,000 stock options at an exercise price of $1.88 per share. Under the net exercise terms, 5,024 shares that would have been issued were instead withheld by the company at a value of $4.49 per share to cover the aggregate exercise price, and 6,976 net shares were issued. Following these transactions, the filing shows 37,563 common shares held directly and 12,314 shares held indirectly through the trust, while the exercised option grant was reduced to zero. The footnotes state the trust is a Spousal Lifetime Access Trust and that Waldman disclaims beneficial ownership of its holdings except for any pecuniary interest.

Apyx Medical Corporation is soliciting proxies for its 2026 Annual Meeting of Stockholders on August 6, 2026, where holders will vote to elect five directors, ratify RSM US LLP as auditor, approve a non-binding say-on-pay resolution, and approve the 2026 Share Incentive Plan.

Stockholders of record at the close of business on June 15, 2026, when 41,912,040 common shares were outstanding, are entitled to vote. The proxy statement also reviews 2025 developments, including FDA 510(k) clearance and commercial launch of the AYON body contouring system, Renuvion’s launch in China, and a November 2025 equity offering of 2,762,431 shares at $3.62 for approximately $9.1 million in net proceeds.

The filing details executive and director compensation, with CEO Charles D. Goodwin’s 2025 total compensation of $1,233,863, an at-risk bonus framework tied to performance, significant stock option grants, and an executive compensation clawback policy. It also highlights governance structures such as a majority-independent board, four standing committees, a lead independent director, a code of ethics, and an insider trading policy.

Apyx Medical Corp Chief Operating Officer Shawn David Roman reported a net stock option exercise through The Roman Family Revocable Trust. On June 15, 2026, he exercised 15,000 stock options at an exercise price of $3.23 per share.

To cover the aggregate exercise price, 10,533 shares of common stock otherwise issuable were withheld by the issuer at a value of $4.60 per share as a tax and exercise-price payment. As a result, 4,467 net shares of common stock were issued to the trust. Following the tax-withholding disposition, the trust held 16,467 shares of Apyx Medical common stock indirectly for the reporting person.

Apyx Medical Corporation has appointed Board Chairman Stavros Vizirgianakis as Executive Chairman under a new letter agreement dated June 11, 2026. In this role, he will provide strategic leadership, governance oversight, support for corporate initiatives, investor engagement, and advice on capital markets and corporate development.

In connection with this appointment and in recognition of his service, the Board granted Mr. Vizirgianakis 450,000 restricted stock units under the 2023 Share Incentive Plan. Of these, 150,000 RSUs vest immediately on June 11, 2026, with two additional tranches of 150,000 RSUs each vesting monthly over 12-month periods starting on the first and second anniversaries of the grant date. He will not be an officer or "executive officer" of the company.

Apyx Medical Corp director Wendy Lauren Levine received a grant of stock options as part of her compensation. She was awarded options to purchase 50,000 shares of Apyx common stock at an exercise price of $4.65 per share, expiring on June 11, 2036. According to the disclosure, the option grant vests ratably over a twelve-month period and becomes fully vested and exercisable on the first anniversary of the grant date. After this award, she holds 50,000 stock options directly.